JO2662B1 - Use of 4-methoxy-cyclopropyl-5, 3-N-dichloro-1-oxoperidine-4-yl-5 (methoxy) pyridine-2-carboxamide in the treatment of spinal cord injuries - Google Patents

Use of 4-methoxy-cyclopropyl-5, 3-N-dichloro-1-oxoperidine-4-yl-5 (methoxy) pyridine-2-carboxamide in the treatment of spinal cord injuries

Info

Publication number
JO2662B1
JO2662B1 JO2008185A JOP20080185A JO2662B1 JO 2662 B1 JO2662 B1 JO 2662B1 JO 2008185 A JO2008185 A JO 2008185A JO P20080185 A JOP20080185 A JO P20080185A JO 2662 B1 JO2662 B1 JO 2662B1
Authority
JO
Jordan
Prior art keywords
oxido
cyclopropylmethoxy
carboxamide
pyridin
dichloro
Prior art date
Application number
JO2008185A
Other languages
Arabic (ar)
English (en)
Inventor
فيليب ديلاي-جويت
باديا فيرزاز
جوسيلين لوليفير
Original Assignee
سانوفي- افنتس
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by سانوفي- افنتس filed Critical سانوفي- افنتس
Application granted granted Critical
Publication of JO2662B1 publication Critical patent/JO2662B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
JO2008185A 2007-04-19 2008-04-17 Use of 4-methoxy-cyclopropyl-5, 3-N-dichloro-1-oxoperidine-4-yl-5 (methoxy) pyridine-2-carboxamide in the treatment of spinal cord injuries JO2662B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0702851A FR2915098B1 (fr) 2007-04-19 2007-04-19 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes de la moelle epiniere

Publications (1)

Publication Number Publication Date
JO2662B1 true JO2662B1 (en) 2012-06-17

Family

ID=38779706

Family Applications (1)

Application Number Title Priority Date Filing Date
JO2008185A JO2662B1 (en) 2007-04-19 2008-04-17 Use of 4-methoxy-cyclopropyl-5, 3-N-dichloro-1-oxoperidine-4-yl-5 (methoxy) pyridine-2-carboxamide in the treatment of spinal cord injuries

Country Status (33)

Country Link
US (1) US8592443B2 (ko)
EP (1) EP2150253B1 (ko)
JP (1) JP5386477B2 (ko)
KR (1) KR101470043B1 (ko)
CN (1) CN101674829B (ko)
AR (1) AR066106A1 (ko)
AT (1) ATE503481T1 (ko)
AU (1) AU2008257321B2 (ko)
BR (1) BRPI0810446A2 (ko)
CA (1) CA2684172C (ko)
CL (1) CL2008001134A1 (ko)
CY (1) CY1111779T1 (ko)
DE (1) DE602008005873D1 (ko)
DK (1) DK2150253T3 (ko)
EA (1) EA015355B1 (ko)
ES (1) ES2363056T3 (ko)
FR (1) FR2915098B1 (ko)
HK (1) HK1142000A1 (ko)
HR (1) HRP20110459T1 (ko)
IL (1) IL201451A (ko)
JO (1) JO2662B1 (ko)
MA (1) MA31369B1 (ko)
ME (1) ME00934B (ko)
MX (1) MX2009011285A (ko)
MY (1) MY146657A (ko)
NZ (1) NZ580483A (ko)
PA (1) PA8776601A1 (ko)
PL (1) PL2150253T3 (ko)
PT (1) PT2150253E (ko)
SI (1) SI2150253T1 (ko)
TW (1) TWI411435B (ko)
UY (1) UY31033A1 (ko)
WO (1) WO2008145840A2 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2915099B1 (fr) 2007-04-19 2009-06-05 Sanofi Aventis Sa Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens
CN104955820A (zh) * 2012-11-28 2015-09-30 赛诺菲 4-(环丙基甲氧基)-n-(3,5-二氯-1-氧化-吡啶-4-基)-5-甲氧基吡啶-2-甲酰胺的制备方法
EP2935219A1 (en) * 2012-11-28 2015-10-28 Sanofi METHOD OF PREPARATION OF CRYSTAL FORMS OF 4-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLORO-1-OXIDOPYRIDYN-4-yl)-5-METHOXYPYRIDINE-2-CARBOXAMIDE AND CRISTAL FORMS THEREOF
WO2022159632A1 (en) 2021-01-20 2022-07-28 Alto Neuroscience, Inc. Enhancement of camp signaling as a combination drug strategy for the treatment of depression and related conditions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
DK0711282T3 (da) * 1993-07-28 2002-09-16 Aventis Pharma Ltd Forbindelser som PDE IV og TNF inhibitorer
GB9401460D0 (en) 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
GB9507297D0 (en) 1995-04-07 1995-05-31 Rh Ne Poulenc Rorer Limited New composition of matter
US6196968B1 (en) 1997-06-02 2001-03-06 General Surgical Innovations, Inc. Direct vision subcutaneous tissue retractor and method for use
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
CA2395196C (en) * 1999-12-23 2006-02-21 Icos Corporation Cyclic amp-specific phosphodiesterase inhibitors
CA2439691A1 (en) * 2001-03-02 2002-09-12 Bristol-Myers Squibb Company Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
EP1519922A1 (en) 2002-07-02 2005-04-06 Merck Frosst Canada & Co. Di-aryl-substituted ethane pyridone pde4 inhibitors
WO2004067006A1 (en) 2003-01-27 2004-08-12 Pharmacia Corporation Combination of a pde iv inhibitor and a tnf-alpha antagonist
WO2005032493A2 (en) * 2003-10-07 2005-04-14 Renovis, Inc. Amide compounds as ion channel ligands and uses thereof
EP1888528A2 (en) * 2005-06-10 2008-02-20 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
US20070021451A1 (en) * 2005-07-20 2007-01-25 Hamamatsu University School Of Medicine Method for preventing or treating neurologic damage after spinal cord injury

Also Published As

Publication number Publication date
AR066106A1 (es) 2009-07-22
JP2010524905A (ja) 2010-07-22
EP2150253B1 (fr) 2011-03-30
CN101674829B (zh) 2012-01-18
DE602008005873D1 (de) 2011-05-12
FR2915098A1 (fr) 2008-10-24
CA2684172A1 (fr) 2008-12-04
TWI411435B (zh) 2013-10-11
KR20090130063A (ko) 2009-12-17
EA015355B1 (ru) 2011-06-30
EP2150253A2 (fr) 2010-02-10
FR2915098B1 (fr) 2009-06-05
US20100137370A1 (en) 2010-06-03
WO2008145840A2 (fr) 2008-12-04
KR101470043B1 (ko) 2014-12-05
MX2009011285A (es) 2009-11-02
MY146657A (en) 2012-09-14
UY31033A1 (es) 2008-11-28
HK1142000A1 (ko) 2010-11-26
CN101674829A (zh) 2010-03-17
DK2150253T3 (da) 2011-07-25
JP5386477B2 (ja) 2014-01-15
PT2150253E (pt) 2011-06-17
WO2008145840A3 (fr) 2009-06-25
AU2008257321B2 (en) 2013-08-15
NZ580483A (en) 2011-06-30
IL201451A0 (en) 2010-05-31
CL2008001134A1 (es) 2009-01-16
PA8776601A1 (es) 2008-11-19
AU2008257321A1 (en) 2008-12-04
US8592443B2 (en) 2013-11-26
IL201451A (en) 2013-04-30
ES2363056T3 (es) 2011-07-19
PL2150253T3 (pl) 2011-08-31
CY1111779T1 (el) 2015-10-07
TW200911248A (en) 2009-03-16
EA200970969A1 (ru) 2010-02-26
CA2684172C (fr) 2015-10-27
ME00934B (me) 2012-06-20
ATE503481T1 (de) 2011-04-15
HRP20110459T1 (hr) 2011-07-31
BRPI0810446A2 (pt) 2014-10-14
MA31369B1 (fr) 2010-05-03
SI2150253T1 (sl) 2011-07-29

Similar Documents

Publication Publication Date Title
MX350234B (es) Compuestos de enlace especificos de bacterias gram-positivas.
MX2011007930A (es) Conjugados de insulina cristalina.
GB0515353D0 (en) Food
MY146112A (en) Long-term feed - cancer patient
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
RS53124B (en) USE OF BETANECOL FOR THE TREATMENT OF XEROSOMOMY
TW200700064A (en) Novel compounds
TW200630367A (en) Substituted adenines and the uses thereof
UA102858C2 (ru) Производные пиридино-пиридинонов, способ их получения и применения в терапии
ZA200706338B (en) 1-H-pyrrole-2-carboxamides and imidazole-5-carboxamides and use thereof as FAK, KDR and TIE2 Kinase modulators for the treatment of cancer
MX342947B (es) Tratamiento de diabetes tipo 2.
IL207965A (en) Compounds to treat or prevent pain
IL177169A0 (en) Use of n- (2-aryl-propionyl)-sulfonamides for the treatment of spinal cord injury
JO2662B1 (en) Use of 4-methoxy-cyclopropyl-5, 3-N-dichloro-1-oxoperidine-4-yl-5 (methoxy) pyridine-2-carboxamide in the treatment of spinal cord injuries
ATE489947T1 (de) Axomadol zur schmerzbehandlung bei arthrose
WO2009074253A3 (en) Clofarabine dietherphospholipid derivatives
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders
MX2011006532A (es) Compuestos anticancerigenos.
MX2009011214A (es) Uso de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-4-piridin-4-il)- 5-(metoxi)piridin-2-carboxamida para el tratamiento de los traumatismos craneales.
MY148092A (en) Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to parkinson's disease
TH0801001896A (th) การใช้ 4-ไซโคลโพรพิลเมธอกซิ-n-(3,5-ไดคลอโร-1-ออกซิโด-ไพริดิน-4-อิล)-5-(เมธอกซิ)ไพริดีน-2-คาร์บอกซามีด ในการรักษาการบาดเจ็บไขสันหลัง
MX2012000625A (es) Compuestos de enlace especificos de bacterias gram-positivas.
UA106224C2 (en) Crystalline insulin-conjugates
UA101379C2 (en) Amidophenoxyindazoles useful in the treatment of cancer
GB0722338D0 (en) Novel use and treatment